503838765 05/23/2016

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3885413

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date	
ELISABETH SOUHAMI	03/16/2016	
LOUISE SILVESTRE	04/11/2016	

## **RECEIVING PARTY DATA**

Name:	SANOFI-AVENTIS DEUTSCHLAND GMBH	
Street Address:	BRÜNINGSTRASSE 50	
City:	FRANKFURT	
State/Country:	GERMANY	
Postal Code:	65929	

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14965586

### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 3129130001

**Email:** docketing@mbhb.com, degiulio@mbhb.com

Correspondent Name: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Address Line 1: 300 SOUTH WACKER DRIVE, 32ND FLOOR

Address Line 4: CHICAGO, ILLINOIS 60606

NAME OF SUBMITTER:	JAMES V. DEGIULIO
SIGNATURE:	/James V. DeGiulio/
DATE SIGNED:	05/23/2016

## **Total Attachments: 4**

source=15-1974\_executed-Assignment#page1.tif source=15-1974\_executed-Assignment#page2.tif source=15-1974\_executed-Assignment#page3.tif source=15-1974\_executed-Assignment#page4.tif

PATENT 503838765 REEL: 038688 FRAME: 0221

#### ASSIGNMENT AND AGREEMENT

For value received and intending to be legally bound, I/we, the undersigned joint inventor(s) (Assignor(s)), sell, assign and transfer to Sanofi-Aventis Deutschland GmbH (Assignee), Brüningstrasse 50, 65929 Frankfurt, Germany and its successors, assigns and legal representatives, the entire right, title and interest in and to my/our invention and any improvements thereon for all countries of the world, relating in and to the application for United States Letters Patent therefore, assigned Attorney Docket No. DE2014/139 US NP, entitled

#### INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION

And for all patent applications which claim priority to or are derived from said priority applications:

European Patent (EP):

EP Application Filing Date:

November 10, 2015

EP Application Filing No.:

15193940.2

EP Application Filing Date:

December 12, 2014

EP Application Filing No.:

14197685.2

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said application(s), and under any and all Letters Patent which may be granted therefore, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, pipelines and extensions, and governmental exclusivity rights of the same.

I/we state that I/we am/are an original inventor(s) of the claimed invention and authorize the filing of a patent application for the claimed invention.

I/we authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

I/we agree that, when requested, I/we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

I/we covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed.

**PATENT** 

REEL: 038688 FRAME: 0222

# sanofi-aventis Docket No. DE2014/139 US NP

I/We hereby acknowledge that any willful false statements made in this assignment are punishable by fine or imprisonment, or both, under Title 18, United States code  $\S 1001$ .

Signed at	JAKIS, 12	ANCE on this Walay of MACON,	2016.		
	(City and Nation) Signature:				
	Inventor's Name: Residential Address:	Elisabeth Souhami c/o SANOFI, Département Brevets, 54 rue La Boétie, 75008 Paris, FR			
Signed at	(City and Nation)	on this day of, 2	2016.		
	Signature:				
	Inventor's Name:	Louise Silvestre c/o SANOFI, Département Brevets, 54 rue La Boétie, 75008 Paris, FR			

PATENT

REEL: 038688 FRAME: 0223

#### ASSIGNMENT AND AGREEMENT

For value received and intending to be legally bound, I/we, the undersigned joint inventor(s) (Assignor(s)), sell, assign and transfer to Sanofi-Aventis Deutschland GmbH (Assignee), Brüningstrasse 50, 65929 Frankfurt, Germany and its successors, assigns and legal representatives, the entire right, title and interest in and to my/our invention and any improvements thereon for all countries of the world, relating in and to the application for United States Letters Patent therefore, assigned Attorney Docket No. DE2014/139 US NP, entitled

# INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION

And for all patent applications which claim priority to or are derived from said priority applications:

European Patent (EP): EP Application Filing Date: November 10, 2015

EP Application Filing No.: 15193940.2

EP Application Filing Date: December 12, 2014

EP Application Filing No.: 14197685.2

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said application(s), and under any and all Letters Patent which may be granted therefore, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, pipelines and extensions, and governmental exclusivity rights of the same.

I/we state that I/we am/are an original inventor(s) of the claimed invention and authorize the filing of a patent application for the claimed invention.

I/we authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

I/we agree that, when requested, I/we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

I/we covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed.

PATENT REEL: 038688 FRAME: 0224

# sanofi-aventis Docket No. DE2014/139 US NP

I/We hereby acknowledge that any willful false statements made in this assignment are punishable by fine or imprisonment, or both, under Title 18, United States code §1001.

Signed at			on this	day of	. 2016
	(City and Nation)		· ·		, 2010
	Signature:				
	Inventor's Name:	Elisabeth Souhami s: c/o SANOFI, Département Brevets, 54 rue La Boétie, 75008 Paris, FR			
<b>.</b>	685 ox				
Signed at	(City and Nation)	Chrice		day of A	, 2016.
	Signature:		and the state of t		
	Inventor's Name:	Louise Silvestre	<i>(</i> ************************************		
	Residential Address:		partement Brev	ets, 54 rue La Boétie	,
		75008 Paris, FR			

PATENT REEL: 038688 FRAME: 0225

RECORDED: 05/23/2016